Follow

Submissions from 2021

Link

Investigational Microbiome Therapeutic SER-109 Reduces Recurrence of Clostridioides Difficile Infection (CDI) Compared to Placebo, Regardless of Risk Factors for Recurrence, Stuart H. Cohen, Thomas J. Louie, Matthew D. Sims, John Pullman, Elaine E. Wang, and Henry Wu

PDF

Cost-Effectiveness Analysis of Recombinant Zoster Vaccine for the Prevention of Herpes Zoster in Immunocompromised Adults Diagnosed with Select Cancers in the United States, Desmond Curran, Brandon Patterson, Justin Carrico, Ahmed Salem, Elizabeth La, Stephane Lorenc, Katherine Hicks, Sara Poston, and Christopher Carpenter

PDF

Cost-Effectiveness of Recombinant Zoster Vaccine for Vaccinating Immunocompromised Adults Against Herpes Zoster in the United States, Desmond Curran, Ahmed Salem, Stephane Lorenc, Brandon Patterson, Justin Carrico, Katherine A. Hicks, Elizabeth M. La, Sara Poston, and Christopher F. Carpenter

Link

COVID-19 Seropositivity and Asymptomatic Rates in Healthcare Workers at Beaumont, Hans Keil and Matthew D. Sims

Link

Time to Recurrence of Clostridioides Difficile Infection (rCDI) is Rapid Following Completion of Standard of Care Antibiotics: Results from ECOSPOR-III, a Phase 3 Double-Blind, Placebo-Controlled Randomized Trial of SER-109, an Investigational Microbiome Therapeutic, Thomas J. Louic, Matthew D. Sims, Richard Nathan, Steven O'Marro, Princy N. Kumar, Elain E. Wang, and Robert Stevens

PDF

Current Challenges in COVID-19 Triaging: A Global Perspective, Mauli Patel, Robin Sudandiradas, Trini Mathew, Paul Kilgore, Mahadev Rao, Chiranjay Mukhopadhay, and Marcus Zervos

Link

Emergence of Colistin Resistance in the OVERCOME Trial: Impact of Combination Therapy With Meropenem, Jason M. Pogue, Michael J. Rybak, Kyle Stamper, Dror Marchaim, Visanu Thamlikitkul, Yehuda Carmeli, and Matthew D. Sims

Link

The Impact of In Vitro Synergy Between Colistin and Meropenem on Clinical Outcomes in Invasive Carbapenem-Resistant Gram-Negative Infections: A Report From the OVERCOME Trial, Jason M. Pogue, Michael J. Rybak, Kyle Stamper, Dror Marchaim, Visanu Thamlikitkul, Yehuda Carmeli, and Matthew D. Sims

Infectious Diseases Research at Beaumont with a Focus on COVID-19, Matthew D. Sims

Link

Kinks and Quirks of Research During A Pandemic., Matthew D. Sims

Link

SARS-CoV-2 Virology and Immunization, Matthew D. Sims

Link

Diagnostic Testing Among Patients With Suspected Recurrent Clostridioides Difficile Infection (rCDI) in ECOSPOR-III a Phase 3 Clinical Trial: Implications for Clinical Practice vs Clinical Trials, Matthew D. Sims, Sahil Khanna, Darrell Pardi, Paul Feuerstadt, Charles Berenson, Henry Wu, and Elaine E. Wang

Link

SER-109, an Investigational Microbiome Therpeutic, Reduces Abundance of Antimicrobial Resistance Genes in Patients with Recurrent Clostridioides Difficile Infection (rCDI) After Standard-of-Care Antibiotics, Timothy J. Straub, Liyang Diao, Christopher Ford, Matthew D. Sims, Thomas J. Louie, Charles Berenson, and Colleen S. Kraft

Submissions from 2019

Link

The Emperor's New Clothes: Prospective Observational Evaluation of the Association between Initial Vancomycin Exposure and Failure Rates among Adult Hospitalized Patients with MRSA Bloodstream Infections (PROVIDE)., Matthew Sims

Submissions from 2017

Link

Mycoplasma genitalium Prevalence and Variability Based on Gender, Race and Sexual Preference in Patients Attending the Oakland County Health Department Disease Clinic, Valida Bajrovic and Paul Chittick

Link

Outcome Based Study of Carbapenem Use Relative to ESBLs (OBSCURE), Otavio Pereira Rodrigues and Matthew Sims

Link

Doing the Same with Less: A Randomized, Multinational, Open-Label, Adjudicator-Blinded Trial of an Algorithm vs. Standard of Care to Determine Treatment Duration for Staphylococcal Bacteremia, Matthew Sims

Link

Potential Impact of Rapid Diagnostics in Management of Suspected Pneumonia, Matthew Sims